View Older Stories
-
BTIG Upgrades Medtronic, Inc. (MDT) to Buy
-
Medtronic, Inc. (MDT) PT Lowered to $101 at Needham
-
Medtronic files to expand Hugo robotic surgery system to new specialties
-
Medtronic invests in two ICE catheter technology companies
-
Medtronic (MDT) Tops Q4 EPS by 1c, Beats on Revenue; Offers FY27 EPS Guidance
-
Medtronic, Inc. (MDT) PT Lowered to $100 at Mizuho
-
Medtronic earnings preview Q4: softer profit expected with restructuring in focus
-
Medtronic (MDT) call put ratio 1 call to 1 put into quarter results
-
Goldman Sachs Reinstates Medtronic, Inc. (MDT) at Neutral
-
Orchestra BioMed receives $20 million from Medtronic under financing pact
-
Medtronic cyberattack does not affect products or operations
-
Medtronic, Inc. (MDT) PT Lowered to $95 at Jefferies
-
Medtronic, Inc. (MDT) PT Lowered to $90 at UBS to Reflect Cllosing of MiniMed IPO
-
Q1 MedTech quarterly preview: BTIG
-
Medtronic (MDT) Reiterated at Hold by Stifel After Physician Survey
-
Medtronic, Inc. (MDT) PT Lowered to $106 at Evercore ISI
-
Medtronic, Inc. (MDT) PT Lowered to $95 at Stifel
-
Medtronic, Inc. (MDT) PT Lowered to $115 at Argus
-
Piper Sandler on BSX and MDT Following KOL Call
-
Medtronic gets FDA clearance for surgical system in brain, ENT procedures
-
Needham Reiterates Buy Rating on Medtronic, Inc. (MDT)
-
BofA Securities on Medtronic, Inc. (MDT): 'one of few accelerating growth companies in medtech'
-
BofA: We see MDT rev accelerating from new bottom-up model
-
Needham Reiterates Buy Rating on Medtronic, Inc. (MDT)
-
Leerink Partners Reiterates Outperform Rating on Medtronic, Inc. (MDT): acquisition an "incremental positive"
-
Needham Reiterates Buy Rating on Medtronic, Inc. (MDT): "glad to see MDT increasingly pursue tuck-in acquisitions"
-
Truist Securities Reiterates Hold Rating on Medtronic, Inc. (MDT) amid acquisition announcement
-
Piper Sandler's Key Takeaways From CRT 2026
-
Medtronic (MDT) files to offer debt
-
Medtronic receives Japan reimbursement for blood pressure device
-
Medtronic, Inc. (MDT) PT Lowered to $103 at Truist Securities
-
Mizuho Reiterates Outperform Rating on Medtronic, Inc. (MDT)
-
Medtronic, Inc. (MDT) PT Lowered to $120 at Needham
-
Medtronic beats Q3 expectations with highest revenue growth in 10 quarters
-
Medtronic (MDT) Tops Q3 EPS by 2c; offers guidance
-
Medtronic preview: product launches, diabetes unit progress boost growth
-
Medtronic (MDT) June 100 calls active into quarter results
-
Medtronic receives FDA clearance for spine surgery robotic system
-
Medtronic (MDT) call put ratio 1 call to 1.4 puts into quarter results
-
Barclays Reinstates Medtronic, Inc. (MDT) at Overweight
-
Needham Upgrades Medtronic, Inc. (MDT) to Buy
-
Leerink: 'MDT remains one of our Top Picks for 2026'
-
Citi Resumes Medtronic, Inc. (MDT) at Buy, Top Pick
-
Medtronic receives Medicare access and FDA clearances for diabetes system
-
Wells Fargo Resumes Medtronic, Inc. (MDT) at Overweight, Remains Top Pick for 2026
-
CICC Starts Medtronic, Inc. (MDT) at Outperform
-
Medtronic receives FDA clearance for MiniMed Go diabetes management system
-
Bernstein Highlights Top U.S. Medtech 2026 Picks: 'Sector Poised For a Rebound'
-
Medtronic (MDT) call put ratio 3 calls to 1 put into the annual J.P. Morgan Healthcare Conference
-
Who in MedTech could get acquired at this year's healthcare investor conference in SF? Piper answers

